

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

upadacitinib oral solution (Rinvoq LQ oral solution)

Notes:

- Quantity Limits: Yes
- ^Adequate trial is defined as the following:
 - Methotrexate for psoriatic arthritis – 3 months
- *Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

Initiation (new start) criteria: Non-formulary **upadacitinib oral solution (Rinvoq LQ oral solution)** will be covered when the following criteria are met:

1. Prescriber is a rheumatologist and patient has a diagnosis of psoriatic arthritis
 - Patient is between 2 to 17 years of age
 - Patient weighs 10 kg to less than 30 kg OR patient weighs 30 kg or more and unable to swallow capsule/tablet dosage forms
 - Patient has failed an adequate trial[^], has an intolerance* to, or has a contraindication to methotrexate (methotrexate not required if patient has dactylitis [inflammation of finger or toe] and/or enthesitis [inflammation of the entheses])
 - Patient has tried and failed, has an intolerance* to, or has a contraindication to at least 1 of the following:
 - Infliximab product (unless documented by prescriber that patient is unable to attend infusion appointments)
 - Adalimumab product (criteria based)
2. Prescriber is a rheumatologist and patient has a diagnosis of juvenile idiopathic arthritis
 - Patient is 2 years of age or older
 - Patient weighs 10 kg to less than 30 kg OR patient weighs 30 kg or more and unable to swallow capsule/tablet dosage forms
 - Patient has tried and failed, has an intolerance* to, or has a contraindication to methotrexate
 - Patient has tried and failed, has an intolerance* to, or has a contraindication to at least 1 of the following:
 - Infliximab product (unless documented by prescriber that patient is unable to attend infusion appointments)
 - Adalimumab product (criteria based)

kp.org

Revised: 03/13/25
Effective: 05/15/25

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

upadacitinib oral solution (Rinvoq LQ oral solution)

Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously: Non-formulary **upadacitinib oral solution (Rinvoq LQ oral solution)** will be covered when the following criteria are met:

1. Prescriber is a rheumatologist and patient has a diagnosis of psoriatic arthritis
 - Patient is between 2 to 17 years of age
 - Patient weighs 10 kg to less than 30 kg OR patient weighs 30 kg or more and unable to swallow capsule/tablet dosage forms
2. Prescriber is a rheumatologist and patient has a diagnosis of juvenile idiopathic arthritis
 - Patient is 2 years of age or older
 - Patient weighs 10 kg to less than 30 kg OR patient weighs 30 kg or more and unable to swallow capsule/tablet dosage forms

kp.org

Revised: 03/13/25
Effective: 05/15/25

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest